Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4,000.00 3,950.00 4,050.00 4,000.00 4,000.00 4,000.00 2,542 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.3 8.2 139.4 28.7 208

Bioventix Share Discussion Threads

Showing 1151 to 1171 of 1475 messages
Chat Pages: Latest  47  46  45  44  43  42  41  40  39  38  37  36  Older
DateSubjectAuthorDiscuss
10/1/2020
08:15
Tipped by Questor
mngf
08/1/2020
18:29
Yes, slowly grinding upwards. I don’t see the share price having much upwards momentum unless there’s some serious news on troponin at the next results.

The share price is still fairly rich based on the latest results.

diviincomesearch
08/1/2020
17:01
HNY holders - gradually creeping back up where she belongs.
igbertsponk
19/12/2019
18:42
There is a detailed report on Bioventix's recent AGM which can be found in our members area here: hTTps://sharesoc.ning.com/xn/detail/6389471:Comment:55228

To access the report, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hTTps://www.sharesoc.org/membership/

Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the report (and reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hTTps://www.sharesoc.org/contact-us/

sharesoc
19/12/2019
16:05
Hopefully significant

hTTPs://emj.bmj.com/content/37/1/8?utm_source=alert&utm_medium=email&utm_campaign=emj&utm_content=toc&utm_term=18122019

Objectives To directly compare the diagnostic accuracy of four decision aids (Troponin-only Manchester Acute Coronary Syndromes (T-MACS), History, ECG, Age, Risk factors and Troponin (HEART), Thrombolysis in Myocardial Infarction (TIMI) and Emergency Department Assessment of Chest Pain (EDACS)) used to expedite the early diagnosis of acute coronary syndromes (ACS) in the ED.

Conclusions In this study, T-MACS could rule out AMI in 46.5% patients with 99.2% sensitivity. EDACS could rule out AMI in 48.3% patients with lower sensitivity, although the difference was not statistically significant. The HEART and TIMI scores had lower diagnostic accuracy.

chippyfriday
19/12/2019
09:11
Https://swiss-nordic-bio-2020.b2match.io/participants/92 The CEO of CardiNor is presenting at Swiss-Nordic Bio in February. CardiNor is developing a secretoneurin assay using a Bioventix antibody. Secretoneurin is an experimental cardiac biomarker for which clinical utility has not yet been established. This year's version of his profile indicates that "The first product is now ready for launch in the research market" and that they are seeking to raise Eur 2m to pursue CE marking. Encouraging that RuO (research use only) launch of secretoneurin is imminent and that things are, more generally, progressing. RuO sales unlikely to be meaningful as secretoneurin not currently widely researched.
gsbmba99
18/12/2019
07:29
hTTps://maynardpaton.com/2019/12/17/bioventix-satisfactory-2019-results-reveal-yet-another-special-dividend-and-indicate-growth-during-2020-2025-depends-entirely-on-troponin/

Without advfn's corruption of http

alter ego
18/12/2019
05:40
hxxps://maynardpaton.com/2019/12/17/bioventix-satisfactory-2019-results-reveal-yet-another-special-dividend-and-indicate-growth-during-2020-2025-depends-entirely-on-troponin/
carcosa
16/12/2019
10:48
Wrong board Sunningdale. Or are you posting that everywhere?
trident5
16/12/2019
10:39
Following on from my previous Open Orphans (ORPH) posts, Cathal Friel has delivered as promised with the all share merger with hVIVO (HVO). Seeing as HVO was trading at 30p at the start of the year, 2.47 ORPH shares for for each HVO share at 15.6p is great value. This follows partnerships with biopharma giant Ipsen Group and Venn’s deal with Carna Bioscience, and will leverage up and commercialise HVO’s sb through the Open Orphan health data platform.

At 5.6p this still values ORPH at just £14m - combine in HVO at £11m plus the preferred partnership agreements and ORPH is set for a big 2020

sunningdale1
28/11/2019
12:45
It's a couple months old but gives a useful overview of progress in beta amyloid blood tests: Https://www.alzforum.org/news/conference-coverage/are-av-blood-tests-ready-prime-time No mention of PRE Diagnostics. Assay precision will be important as, apparently, the difference between a positive and negative determination is as little as 10-15%. Some very high costs/test being achieved. "When pressed, Shimadzu representatives allowed that they were currently selling their service in Japan at a list price of about $1,000 per test and an actual negotiated rate of between $500 and $900." "C2N representatives told Alzforum that the current price for pharma and research use comes to roughly $700 per sample." Trials to assess clinical utility for the PRE/Bvxp test should be underway/starting shortly.
gsbmba99
26/11/2019
11:01
For those interested in other Pharma/bio stocks, Maurice Treacy, CCO of Open Orphan #ORPH reveals they have signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform on the Vox Podcast.

The interview starts at 10 minutes.

hxxps://audioboom.com/posts/7433540-nuformix-open-orphan-zoetic-international-and-live-company-group

sunningdale1
22/11/2019
11:07
An interesting response to yesterday's research from a professor of interventional cardiology. Https://twitter.com/NickCurzen/status/1197546513221718019 "Fascinating result.... a much better use for troponin than diagnosing acute mi.... biomarker for lifespan?" Judging by the "likes", he isn't the only academic who thinks this. Applications for troponin beyond A&E could lead to a larger market opportunity for the Siemens test.
gsbmba99
21/11/2019
12:08
New research from ICL in BMJ on troponin - Https://www.bmj.com/content/367/bmj.l6055 with ICL article Https://www.imperial.ac.uk/news/194029/small-rise-heart-attack-protein-linked/ "A positive troponin result is therefore highly clinically meaningful, regardless of age, with the excess mortality associated with a raised troponin level being heavily concentrated in the first few weeks." "They also found that even when doctors do not think the primary problem is a heart attack, the presence of a raised troponin in the blood signifies an increased risk of death. Therefore, the troponin result provides meaningful information in all age groups, regardless of the underlying problem."
gsbmba99
20/11/2019
08:20
Liontrust increased from 7.68% to 10.16%

Makes a change.

11_percent
09/11/2019
15:00
That's a fair point gnnmartin.

I could extend that logic further though - assume the test shows a lack of vitamin D, and it is fixable by sunlight exposure rather than supplementation. Unfortunately, fixing with sunlight exposure is not always so easy - or even possible [he says, gazing out of the window onto a particularly gloomy UK scene].

So why even bother doing the test, if what it shows can't be easily remedied with a handful of pills?

Cheers.

spann_703
09/11/2019
13:09
I read the article. It postulates that what is bad for health is not lack of vitamin D, but lack of sunlight. My first reaction was that this would be bad news for BVXP, but on reflection I am less concerned. Lack of vitamin D may not be an indicator for vitamin D supplements, but it remains an excellent indicator of insufficient exposure to sunlight.
gnnmartin
09/11/2019
11:46
spann_703, thank you.
I enjoyed reading the article

piedro
09/11/2019
10:27
Piedro, I posted this article on the issue a short while back which you may find interesting:

https://bit.ly/2RJnDzP

IMO the evidence that supplementing with Vitamin D is beneficial is sketchy at best.

You will have to form your own judgement as to the potential impact to Bioventix - given the revenue split my opinion is that it has to be a concern.

Boros10 earlier made the point that a change in thinking on Vitamin D is unlikely to happen quickly, but given the information age we live in it's a view I don't share.

spann_703
09/11/2019
10:00
Seems to be saying that our assumptions that bad stuff happens if you're vitamin D deficient was wrong. After bad things happen you can become vitamin D deficient.

Not the first time this idea has been aired.

trident5
09/11/2019
09:22
Could someone knowledgeable comment on this article and if it has any relevance to BVXP

November 8, 2019
Vitamin D and Health Outcomes
Then Came the Randomized Clinical Trials
Anika Lucas, MD1; Myles Wolf, MD, MMSc1,2
https://tinyurl.com/yxpac8xu

- TIA

piedro
Chat Pages: Latest  47  46  45  44  43  42  41  40  39  38  37  36  Older
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230208 00:53:04